SNMMI In The News
May 9, 2012
Amyloid Imaging: The Next Frontier in Alzheimer’s Care
With the FDA approval last month of the radioactive diagnostic agent florbetapir, the industry continued the trend toward improved identification of beta-amyloid, the brain plaque associated with Alzheimer’s disease. Questions still exist about how best to use these tracers, but industry experts view these developments as significant positives for patient care.